STAT June 6, 2024
Allison DeAngelis, Adam Feuerstein

How did advisers react to the first psychedelic therapy to go before the Food and Drug Administration? And did the American Society of Clinical Oncology meeting surpass expectations?

We discuss that and more in this week’s episode of “The Readout LOUD.” STAT colleague Meghana Keshavan joins us to dissect Lykos Therapeutics’ meeting with an FDA advisory committee. We also discuss the latest news in the health and life sciences, including stories from major...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, FDA, Govt Agencies, Pharma, Pharma / Biotech, Trends
Related Articles:
Cell and Gene Therapies — Improving Access and Outcomes for Medicare and Medicaid Beneficiaries
Americans split on using weight loss drugs to treat obesity: Survey
ASHP to CMS: 'Change course' on drug pricing
New AI model predicts gene expression across human cell types
Most Ditch GLP-1 Drugs for Weight Loss Within a Year

Share This Article